DailyDoctor Archive Specialties Get app
Back to the 16 September 2026 edition

Research · 02 of 07

HPI-guided care was not superior to treating at MAP 73 mmHg

Before paying for HPI, try treating earlier: a MAP trigger around 73 mmHg was not shown to be worse.

Design
Open-label, parallel-group randomised trial, 2 centres
Population
100 adults having major non-cardiac surgery with invasive arterial monitoring
Primary outcome
Time-weighted average MAP below 65 mmHg
Effect
Median 0.07 (HPI) vs 0.16 mmHg (MAP ≤73), P=0.119

This open-label trial at two centres randomised 100 adults having major non-cardiac surgery with arterial monitoring to Hypotension Prediction Index (HPI) guided treatment (trigger HPI 85 or more) or a higher MAP trigger (73 mmHg or less), using the same haemodynamic protocol.

Median time-weighted average hypotension below 65 mmHg was 0.07 mmHg with HPI and 0.16 mmHg with the MAP trigger (P=0.119). Area under the threshold was 22 vs 59.7 mmHg·min (P=0.172). Hypertension burden, noradrenaline dose, length of stay and 30-day mortality did not differ.

Earlier trials favouring HPI were open-label and may have carried performance bias. The argument has been that much of HPI's benefit comes from simply treating earlier, at a higher pressure. This trial tested that directly.

It was designed for superiority, so it shows HPI was not proven better, not that the two are equivalent.

  • Compare any HPI evidence against a proactive MAP trigger, not a reactive 65 mmHg one.
  • The numerical trend favoured HPI on hypotension burden; a larger trial could still find a difference.
  • Clinical outcomes were not different in this small trial.
  • Consider cost and monitoring requirements before adopting HPI.

Why it matters

It supports the view that treating hypotension earlier, not the proprietary algorithm, drives most of the benefit.

Don't overread it

With 100 patients and an open-label superiority design, this trial cannot show that HPI and a MAP trigger are equivalent.

The statistics, in plain English

A non-significant result in a superiority trial means the study did not prove a difference, not that there is none. Medians of 0.07 and 0.16 mmHg with P=0.12 suggest a possible difference too small for 100 patients to confirm.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

airwaymgmtperioperativegeneralanaes

Tomorrow morning, before your first patient

One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app